Test compounds and investigate disease biology with the first-in-class IN MATRICO™ Fibrosis Platform, which uses human fibrotic tissue-derived ECMs – defining components of the human fibrotic disease microenvironment – in physiologically-relevant phenotypic cell-based assays.
LUNG FIBROSIS
IN MATRICO™ Lung Fibrosis platform incorporates human lung ECMs from normal and fibrotic lungs to study disease mechanisms and evaluate compounds for ILD, IPF, and other fibrotic lung diseases.
LIVER FIBROSIS
IN MATRICO™ Liver Fibrosis platform incorporates human liver ECMs from normal, fibrotic, and cirrhotic livers to evaluate compounds for fibrotic liver diseases including NASH, ASH, and NAFLD and study disease biology.
